Pregled bibliografske jedinice broj: 160173
Analysis of Immunologic Parameters in Patients with Systemic Lupus Erythematosus
Analysis of Immunologic Parameters in Patients with Systemic Lupus Erythematosus // 12th International Congress of Immunology and 4th Annual Conference of FOCIS Late Abstracts Supplement
Montréal, Kanada, 2004. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 160173 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Analysis of Immunologic Parameters in Patients with Systemic Lupus Erythematosus
Autori
Soldo-Jureša, Dragica ; Cepika, Alma-Martina ; Morović-Vergles, Jadranka ; Gagro, Alenka
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
12th International Congress of Immunology and 4th Annual Conference of FOCIS Late Abstracts Supplement
/ - , 2004
Skup
12th International Congress of Immunology and 4th Annual Conference of FOCIS
Mjesto i datum
Montréal, Kanada, 18.07.2004. - 23.07.2004
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
systemic lupus erythematosus; Toll-like receptors
Sažetak
Systemic lupus erythematosus (SLE) is a chronic disease of autoimmune origin seen predominately in women between the ages of 20 and 40. The disease is life-long, and accompanied with damages of multiple organ systems such as kidneys, heart, joints, skin, lungs and central nervous system. Our study involved so far four newly-discovered SLE patients, which underwent the same therapy protocol, and their healthy, age- and gender-matched controls. The effect of corticosteroids alone or in combination with chloroquine on the level of complement components, lupus-specific auto-antibodies and immunoglobulins in peripheral blood was measured at three time points: before therapy, after three weeks and three months of therapy. In addition, the percentage of Toll-like receptor (TLR)-expressing peripheral blood mononuclear cells (TLR2, TLR4 and TLR9) was determined by three-color immunofluorescence analysis on a flow cytometer. In all patients corticosteroid dose was gradually lowered when chloroquine was introduced in therapy protocol (three weeks after the onset of therapy). Our preliminary results showed the difference in these parameters during the course of therapy.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
0021004
Ustanove:
Imunološki zavod d.d.
Profili:
Alma-Martina Cepika
(autor)
Dragica Soldo-Jureša
(autor)
Alenka Gagro
(autor)
Jadranka Morović-Vergles
(autor)